Strategic Partnerships Sensome has a track record of collaborating with major robotic and guidewire partners (Robocath, Asahi Intecc) to integrate its Clotild Smart Guidewire System with next-generation interventional robotics, presenting a clear avenue for co-sell opportunities with vascular and neurointerventional device manufacturers.

Clinical Validation Recent successful Proof-of-Concept deployments in collaboration with Robocath and ongoing first-in-human/POC studies position Sensome as a credible innovator in intraoperative tissue sensing, enabling opportunities to approach hospitals and clinics for adoption in stroke and neurovascular procedures.

Regulatory & Quality With EN ISO 13485:2016 certification, Sensome demonstrates a mature quality management framework suitable for medical devices, easing conversations with hospital procurement and potential OEM partners seeking compliant, high-quality sensing solutions.

Market Fit Focus on interventional cardiology and neurovascular applications where clot characterization and tissue analysis can enhance procedural safety and outcomes, aligning with interests of leading robotic surgery platforms and guidance-wire manufacturers.

Funding & Growth Recent investor backing and strategic collaborations signal financial support and growth potential, making Sensome an attractive partner for joint ventures, co-development deals, or pilot programs with medical device companies and regional distributors.